Valneva Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Valneva Bundle
Business Model Canvas for vaccine innovators - investor-ready insights & editable templates
Unlock the full strategic blueprint behind Valneva’s business model with our Business Model Canvas—three to five concise, investor-ready insights into how Valneva creates value, scales vaccines, and secures partnerships. Download the complete, editable Word and Excel files to benchmark, plan, and present with confidence. Purchase now to access all nine building blocks and practical analysis.
Partnerships
Pfizer alliance
The Pfizer alliance co-develops and co-commercializes VLA15, combining Valneva’s vaccine expertise with Pfizer’s late-stage development and global commercialization scale. The agreement includes milestone payments, shared development costs and royalties linked to regulatory approvals and sales. As of 2024 the partnership is positioned to mitigate development risk and accelerate global market access for the Lyme vaccine.
Global health funders
Engagements with CEPI and public health agencies de-risk Valneva’s emerging infectious disease programs, leveraging CEPI’s mobilization of over $1.5 billion since 2017 to accelerate vaccine R&D. Non-dilutive funding underwrites clinical trials, manufacturing readiness and outbreak response, aligning Valneva’s portfolio with public health priorities and access provisions and strengthening credibility in neglected/emerging pathogens.
Regulatory bodies
Valneva works continuously with FDA, EMA, MHRA and 30+ national authorities for approvals and lifecycle management. Scientific advice and rolling reviews (used in multiple 2022–24 filings) accelerate timelines and evidence generation. Post-marketing safety commitments, including 15-day serious safety reports, are coordinated closely. Partnerships facilitate labeling, lot release and global registrations.
CMOs and suppliers
CMOs and suppliers provide qualified antigen production, fill-finish, adjuvants and specialty components, with validated quality agreements in place to meet GMP standards.
Dual sourcing and formal quality agreements secure supply continuity and enable technical transfers that allow surge capacity within weeks to months when demand spikes.
These partnerships support cost control and scalability across Valneva products, reducing operational risk and shortening time-to-market.
- qualified partners for antigen, fill-finish, adjuvants
- dual sourcing + quality agreements
- technical transfers enable surge capacity
- supports cost control and scalability
Distributors and clinics
Alliances with wholesalers, specialty distributors and travel/occupational health networks extend Valneva's reach into hospitals, pharmacies and vaccination centers globally, improving vaccine access. Joint demand planning with partners reduces stockouts and optimizes inventory turnover. Localized promotion and point-of-care education increase uptake in target markets.
- Distribution partnerships
- Joint demand planning
- Point-of-care education
Partners support pivotal 2024 trials, over 1.5bn public funding and GMP surge
Key partnerships: Pfizer co-develops/co-commercializes VLA15 (pivotal trials 2024); CEPI/public agencies provide non-dilutive funding (CEPI mobilized >1.5bn since 2017); regulators (FDA/EMA/MHRA +30 authorities) enable rolling reviews; CMOs/dual-sourced suppliers ensure GMP supply and surge capacity; distributors/wholesalers expand market reach.
| Partner | Role | 2024 status |
|---|---|---|
| Pfizer | Co-dev/commercialize | Pivotal trials |
| CEPI | Funding/accelerator | Supports trials; >1.5bn mobilized |
| CMOs | Manufacture/surge | Dual sourcing, GMP |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Valneva mapping the 9 BMC blocks to its vaccine-focused value propositions, R&D and manufacturing capabilities, regulatory and commercial channels, strategic partnerships, and revenue streams. It highlights competitive advantages, sector risks, and funding needs to support strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Valneva’s business model with editable cells to quickly pinpoint vaccine pipeline, revenue streams, and strategic risks; ideal for boardrooms or teams needing a concise, shareable snapshot that saves hours of formatting.
Activities
Vaccine R&D
Valneva's Vaccine R&D focuses on discovery, antigen design and formulation across target pathogens, advancing candidates through preclinical validation where typical attrition rates reach 70–80% and immunogenicity optimization is core. Platform and adjuvant selection target safety-efficacy trade-offs, with adjuvants often boosting antibody titers 2–5x in studies. Pipeline prioritization weighs unmet needs against commercial potential and market size to allocate resources.
Clinical development
Design and execution of Phase 1–3 trials focus on safety, immunogenicity and efficacy, with Phase 3 cohorts typically ranging from several thousand to tens of thousands of participants. Global site management and centralized data systems ensure data integrity and GCP compliance across regions. Biostatistics and predefined interim analyses drive go/no-go decisions and adaptive enrollment. Trials in endemic regions and diverse patient populations support broader, label-strengthening efficacy claims.
Regulatory affairs
Regulatory affairs prepares IND/CTA and BLA/MAA dossiers and manages timely responses to agency queries, leveraging Valneva’s EC-approved COVID-19 vaccine VLA2001 (approved 2021) as a precedent. They coordinate inspections, pharmacovigilance plans and label negotiations across territories. Teams drive risk‑management and post‑approval commitments and ensure lifecycle compliance across markets. Activities support product approval and commercial access.
GMP manufacturing
GMP manufacturing covers scale-up, validation and routine production of Valneva vaccines with stringent in-process controls, batch release testing and end-to-end cold-chain logistics to protect potency.
Tech transfers to internal lines or CMOs provide flexibility for surge capacity and regulatory compliance; continuous improvement programs target yield increases and lower cost per dose.
- Scale-up: validation to routine GMP production
- Quality: in-process controls & batch release testing
- Logistics: validated cold-chain management
- Flexibility: internal/CMO tech transfers
- Efficiency: continuous yield & cost improvements
Market access
Market access combines health-economic modeling, pricing and reimbursement strategies aligned to 2024 HTA requirements to demonstrate value and secure favorable tariffs. Active engagement with NITAGs and procurement agencies drives recommendations and inclusion in national schedules. Medical education and KOL development increase clinical uptake while forecasting and tender participation secure contracted volumes.
- HE modeling aligned to 2024 HTA
- NITAG/procurement engagement
- KOL-led medical education
- Forecasting + tender participation
Vaccine R&D: 70-80% preclinical attrition, GMP scale-up and HTA access
Vaccine R&D: discovery, antigen/formulation, preclinical attrition 70–80% and adjuvants boosting titers ~2–5x. Clinical: Phase 1–3 focusing safety/immunogenicity; Phase 3 cohorts range from several thousand to tens of thousands. Manufacturing: GMP scale‑up, tech transfers to CMOs, cold chain and batch testing. Market access: HE modeling aligned to 2024 HTA, NITAG engagement and tendering.
| Metric | Value |
|---|---|
| Preclinical attrition | 70–80% |
| Adjuvant titer boost | 2–5x |
| Phase 3 size | several thousand–tens of thousands |
| HTA alignment | 2024 |
What You See Is What You Get
Business Model Canvas
The document you’re previewing is the actual Valneva Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive this exact file—complete, formatted, and ready to edit. The full deliverable is provided in Word and Excel so you can present, customize, or share it immediately.
Resources
IP portfolio
Patents, know-how and trade secrets cover antigens, adjuvants and manufacturing processes, protecting Valneva’s differentiation in Lyme (VLA15) and chikungunya (VLA1553) pipelines; patents grant 20-year statutory protection and typically deliver 8–12 years of effective exclusivity post-approval (as of 2024), extending licensing leverage and supporting premium pricing and partnership value.
GMP facilities
GMP facilities encompass dedicated manufacturing plants, onsite QC laboratories, and integrated cold-chain infrastructure to ensure product integrity from antigen synthesis through distribution.
Qualified equipment and validated processes underpin batch-to-batch reliability and regulatory compliance across release testing and stability programs.
Internal capacity for antigen production and fill-finish gives Valneva direct control over supply and timelines, while scalable production lines enable lifecycle management and rapid surge response.
Clinical datasets
Clinical datasets provide comprehensive safety and immunogenicity data across indications, including phase 3 datasets of approximately 4,000 participants for VLA2001. Real-world evidence and post-marketing data from over 100,000 administered doses by 2024 enhance credibility with regulators and payers. These data support label expansions and health technology assessments and inform lifecycle improvements and risk management.
Talent and experts
Valneva leverages multidisciplinary teams across immunology, process engineering, regulatory and HEOR to support marketed vaccine Ixiaro and its pipeline; program management ensures cross-functional execution and faster go/no-go decisions. Established vendor and investigator networks, plus manufacturing sites in Sweden and Scotland, shorten timelines while institutional knowledge lowers development risk.
- Teams: immunology, process, regulatory, HEOR
- Program management: cross-functional execution
- Networks: vendors & investigators accelerate timelines
- Assets: institutional knowledge reduces development risk
Quality systems
Valneva’s quality systems integrate a robust QMS, pharmacovigilance systems and regulatory compliance frameworks to ensure audit readiness and alignment with EMA and FDA requirements; the company reported over 1,200 employees in 2024 supporting manufacturing and quality assurance. Batch release, deviations and CAPA workflows are tightly managed to protect product release integrity and maintain trust with authorities and customers.
- QMS: centralized control and documentation
- PV systems: continuous safety monitoring
- Compliance: audit-ready processes
- Operations: strict batch release, deviation and CAPA handling
Patents + GMP Sweden/Scotland; 8-12 yrs, 1,200
Patents and know-how secure antigen/adjuvant/process exclusivity, yielding ~8–12 years effective post-approval protection (as of 2024).
GMP plants in Sweden and Scotland, internal antigen and fill-finish capacity, scalable lines; 1,200 employees (2024).
Clinical: VLA2001 phase‑3 ~4,000 subjects; >100,000 administered doses by 2024; robust QMS/PV supporting approvals.
| Resource | Metric | Value |
|---|---|---|
| IP | Effective exclusivity | 8–12 yrs (2024) |
| Manufacturing | Employees/sites | 1,200; Sweden, Scotland |
| Clinical | Datasets/doses | Phase‑3 ~4,000; >100,000 doses |
Value Propositions
Unmet needs focus
Targets diseases with limited prophylaxis through clinical-stage programs VLA15 (Lyme) and VLA1553 (chikungunya); CDC estimates ~476,000 Lyme infections annually in the US. Prioritizes meaningful clinical benefit and population impact, aiming to reduce disease burden in endemic regions and travelers. Offers differentiated safety and immunogenicity profiles versus legacy solutions.
Proven safety
Rigorous clinical evaluation and ongoing pharmacovigilance form the backbone of Valneva's safety profile, with comprehensive trial data submitted to regulators. Transparent labeling and proactive risk management communications increase clinician and patient confidence in product use. Quality-by-design manufacturing practices reduce lot-to-lot variability and strengthen supply reliability. These elements support regulatory approvals and clinician adoption globally.
Strong efficacy
Immunogenic formulations engineered for durable protection support Valneva’s positioning, with Phase 3 endpoints and seroprotection rates used to define target populations and label claims. Accruing real-world effectiveness and safety data in post-marketing surveillance strengthens uptake over time. Robust clinical endpoints enable inclusion in national guidelines and competitive tender bids.
Reliable supply
Reliable supply: diversified sourcing and validated capacity enhance continuity, while stringent cold-chain and inventory controls reduce shortages; Valneva plans rapid scaling for outbreaks or demand spikes, strengthening trust with governments and providers.
- Diversified sourcing
- Validated capacity
- Cold-chain controls
- Rapid outbreak scaling
- Government and provider trust
Convenient dosing
Convenient dosing schedules are optimized to improve adherence and access, prioritizing single-dose or short-course regimens where clinically feasible to boost uptake. Clear administration guidance for providers reduces errors and supports rapid deployment in outpatient and mass-immunization settings. Fewer required clinic visits minimize burden on healthcare systems and lower delivery costs.
- Adherence-focused dosing
- Single-dose/short-course priority
- Provider-friendly administration guidance
- Reduced clinic visits and system burden
Short-course Lyme and chikungunya vaccines; US Lyme ~476,000 cases
Clinical-stage vaccines VLA15 (Lyme) and VLA1553 (chikungunya) target diseases with limited prophylaxis; CDC estimates ~476,000 US Lyme infections annually. Differentiated safety/immunogenicity, quality-by-design manufacturing and validated cold-chain enable reliable supply and rapid outbreak scaling. Adherence-focused single/short-course dosing reduces clinic visits and delivery costs.
| Metric | Value |
|---|---|
| US Lyme annual cases (CDC) | ~476,000 |
| Programs | VLA15, VLA1553 (clinical-stage) |
| Dosing focus | Single/short-course |
Customer Relationships
Medical education
Medical education leverages peer-to-peer programs, live webinars, and evidence-based scientific materials for HCPs to raise disease awareness, clarify guidelines, and support correct vaccine administration. Field medical teams respond to real-world evidence and individual HCP requests, feeding insights into positioning and label-appropriate use. In 2024 these activities prioritize building informed advocacy and reducing administration errors through targeted, measurable engagement.
Key account support
Dedicated key-account teams for ministries, payers and large providers deliver joint planning for tenders, forecasting and logistics, aligning with Valneva’s 2024 global commercial footprint and ~1,300 employees. Customized contracts and service-level agreements enable tailored delivery and cold-chain support. This model strengthens retention and underpins multi-year supply agreements, improving revenue visibility for institutional customers.
Pharmacovigilance
Valneva operates 24/7 pharmacovigilance with serious adverse events reported within 7 days and routine follow-ups per regulatory PSUR/PBRER schedules; signal detection and periodic safety updates in 2024 supported trust across markets. Continuous feedback loops feed labeling and training updates, reducing risk exposure and demonstrating measurable commitment to patient safety.
Patient engagement
Clear vaccination guidance and disease information, combined with scheduling and reminder tools, improves adherence and patient satisfaction; reminder systems have been shown to raise vaccine-series completion by up to 25% in studies through 2024. Multilingual materials expand accessibility, particularly in diverse markets where nonnative speakers comprise over 20% of patients in many EU/US regions, boosting uptake and retention.
- guidance: concise disease and vaccine info
- reminders: scheduling + automated follow-ups (up to +25% completion)
- multilingual: +accessibility in >20% diverse-population areas
- outcome: higher adherence and patient satisfaction
Partner co-marketing
Partner co-marketing aligns messaging and campaigns with strategic partners to deliver a consistent brand and clinical narrative; 2024 industry data shows co-marketing can boost engagement 25–40% and reduce cost-per-acquisition ~25%. Shared data and insights refine targeting, improving conversion rates and enabling joint events that expand reach efficiently across partner channels.
- Aligned messaging: consistent clinical narrative
- Data sharing: refines targeting, raises conversion
- Joint events: expand reach, lower CAC ~25%
- Engagement lift: 25–40% (2024 industry studies)
Medical education, 24/7 pharmacovigilance and co-marketing drive retention and revenue
Medical education, field medical insights, 24/7 pharmacovigilance (SAE reporting within 7 days), key-account management (Valneva ~1,300 employees), reminder systems (+up to 25% completion) and partner co-marketing (engagement +25–40%, CAC −~25% in 2024) drive retention, safety and predictable institutional revenue.
| Metric | 2024 Value |
|---|---|
| Employees | ~1,300 |
| Reminder uplift | +up to 25% |
| Co-marketing lift | +25–40% |
| CAC reduction | ~25% |
Channels
Government tenders
Direct participation in national and regional tenders secures large public-sector supply, with public procurement accounting for roughly 80% of global vaccine volumes; Valneva aligns offers to NITAG recommendations and national budget cycles. Multi-year tender wins provide predictable demand and revenue visibility, supporting production planning and cost control. This channel enables broad population coverage through national immunization programs and routine procurement.
Wholesalers
Distribution through specialty and full-line wholesalers extends Valneva vaccine availability to hospitals, pharmacies and clinics across key markets. Aggregated logistics via wholesale partners reduce per-shipment complexity and lower distribution costs. This channel improves service levels and accelerates inventory turns, supporting timely supply to care settings.
Travel clinics
Valneva leverages established travel medicine and occupational health clinic networks to reach travelers at elevated risk for Japanese encephalitis and chikungunya; Japanese encephalitis causes an estimated 68,000 symptomatic cases annually. Provider education programs train clinicians to embed Ixiaro and candidate chikungunya vaccines into routine pre-travel consults. This channel generates predictable private-pay demand through out-of-pocket travel immunizations and employer-sponsored occupational health programs.
Digital platforms
Digital platforms combine professional portals, e-detailing and integrated ordering to centralize Valneva’s customer interactions; by 2024, 70% of life-science firms reported higher HCP engagement via digital channels (Deloitte 2024). Data-driven engagement enables personalized content and targeting, streamlining replenishment, support and compliant material distribution to expand reach.
- #professional-portals: centralized HCP access
- #e-detailing: personalized content delivery
- #ordering-systems: automated replenishment
- #data-driven: analytics for segmentation
- #compliance: audited material distribution
Partner salesforce
Partner salesforce leverages partners’ global commercial infrastructure, accelerating market entry and guideline adoption; in 2024 Valneva’s partner network reached 30+ countries, shortening rollout timelines in priority regions. Shared KPIs align execution and optimize coverage where epidemiology and payer access matter most.
- Reach: 30+ countries (2024)
- Focus: priority geographies
- Governance: shared KPIs
Public-tender vaccine model: ≈80% volumes, 30+ countries, 70% HCP engagement
Valneva secures predictable volume via public tenders (public procurement ≈80% of global vaccine volumes) and multi-year wins; partner salesforce covered 30+ countries in 2024 to accelerate rollout. Wholesale distribution cuts logistics cost and boosts hospital/pharmacy reach. Travel/occupational channels drive private-pay demand (JE ≈68,000 symptomatic cases/year). Digital portals raised HCP engagement (70% by 2024).
| Metric | Value (2024) |
|---|---|
| Public procurement share | ≈80% |
| Partner coverage | 30+ countries |
| HCP digital engagement | 70% |
| JE symptomatic cases | ≈68,000/yr |
Customer Segments
Public purchasers
Public purchasers — ministries of health, defense and regional authorities — buy via national and supranational tenders for population programs and outbreak response, driving bulk demand and long-term forecasting. They prioritize reliability, cost-effectiveness and safety; procurement decisions and reimbursement schemes materially affect uptake. WHO estimates vaccines prevent 2–3 million deaths annually, underscoring public-purchaser impact.
Healthcare providers
Hospitals, clinics, pharmacies and travel medicine centres are primary channels administering Valneva vaccines and counselling patients, driving uptake across inpatient and outpatient settings. They demand clear protocols and stable supply—pharmacy-based programmes delivered up to 50% of adult vaccines in several EU countries in 2024. Reliable distribution and training in these sites are key to real-world adoption and coverage.
Endemic populations
Residents in ~24 JE-endemic countries face ~68,000 clinical JE cases/year (WHO); Lyme causes an estimated 476,000 US infections annually (CDC); chikungunya triggers periodic outbreaks with hundreds of thousands affected. Routine or targeted immunization plus price/access programs and Gavi/public health partnerships are critical to scale uptake and equity.
Travelers and workers
International travelers and at-risk occupational groups (eg, healthcare and flight crews) are core Valneva customers; UNWTO reported 2024 international arrivals recovered to about 86% of 2019 levels, sustaining travel vaccine demand. Purchases are often private-pay or employer-sponsored; convenience, clinic availability and pricing drive uptake, while travel advisories and employer policies strongly influence timing.
- Customer: international travelers, at-risk workers
- Payment: private-pay or employer-sponsored
- Buying drivers: convenience, availability, price
- Triggers: travel advisories, employer vaccine mandates/policies
Pharma partners
Pharma partners: large biopharma seek Valneva for co-development or in-licensing of specialized platforms and assets, sharing clinical and commercial risk while expanding geographic reach and commercial scale; typical deals feature up-fronts €10–200m, milestone pools €50–500m and royalties ~8–20%, with cost-sharing often covering 30–70% of dev expenses.
- co-development / in-license
- up-front €10–200m
- milestones €50–500m
- royalties 8–20%
- cost-share 30–70%
Tenders, pharmacies steer 2024 vaccine demand; travel at 86% of 2019
Public purchasers (national/supranational) drive bulk demand via tenders and account for long-term forecasts; 2024 procurement dynamics and reimbursement determine uptake. Hospitals/clinics/pharmacies deliver most doses—pharmacy programmes supplied up to 50% of adult vaccines in several EU countries in 2024. Travelers/occupational groups (private-pay/employer) follow travel advisories; 2024 arrivals ~86% of 2019, supporting travel-vaccine demand.
| Segment | 2024 metric | Payment/driver |
|---|---|---|
| Public purchasers | Tenders; bulk volumes | Cost, safety, reliability |
| Care sites | Pharmacy up to 50% adult doses | Supply stability, protocols |
| Travelers/workers | Intl arrivals ≈86% of 2019 | Convenience, price |
Cost Structure
R&D expenses
Discovery and preclinical work are concentrated costs in early Valneva programs, typically low single-digit to low double-digit million euros, while Phase I–III trials drive expenses: Phase I ~5–20m, Phase II ~20–60m and pivotal Phase III often 50–300m. CRO fees, site payments and trial manufacturing add large variable costs, and scaling pivotal studies materially increases spend; strict portfolio focus in 2024 helps manage burn rate.
Manufacturing COGS
Manufacturing COGS at Valneva include raw materials for antigen production, on-site antigen fermentation at the Livingston, Scotland facility, and downstream fill-finish operations plus extensive QC testing.
Yield optimization and scrap reduction directly improve margins, while cold-chain storage and specialized logistics add incremental per-dose costs.
Scaling production lowers fixed cost per dose and materially improves unit economics.
SG&A and launch
SG&A and launch spending for Valneva in 2024 prioritized scaling commercial teams, marketing, and medical affairs to support product rollouts. Market access and tender participation incurred recurring fees and bid-related costs. Ongoing education and training programs for HCPs and distributors sustained adoption. Post-launch field support and pharmacovigilance investments maintained uptake and compliance.
Regulatory and QA
Regulatory and QA at Valneva drive recurring costs for submission preparation, regulatory inspections, and compliance systems to secure approvals and renewals; pharmacovigilance operations and post‑marketing safety studies sustain product licenses and public trust. Lot release, batch audits and external audits maintain GMP standards and enable market access across jurisdictions. These functions are continuous cost centers tied to lifecycle management and renewal timelines.
- Submission prep, inspections, compliance systems
- Pharmacovigilance and safety studies
- Lot release, audits, GMP maintenance
- Essential for approvals and renewals
Partnership outlays
Partnership outlays at Valneva involve cost-sharing for co-development and milestone payments that allocate R&D risk across partners, while tech transfers to CMOs and integration expenses fund scale-up and regulatory compliance to accelerate timelines.
- Cost-sharing: reduces Valneva R&D burden, aligns milestone incentives
- Tech transfer: CMO integration and validation costs
- Alliance management: legal, governance, and IP protection expenses
- Benefit: enables faster scale and market reach
R&D front‑loaded: trials €5–300m, scaling lowers COGS
R&D is front‑loaded: discovery/preclinical low single‑ to low double‑digit €m, Phase I ~5–20m, Phase II ~20–60m, Phase III 50–300m; 2024 focus reduced pipeline spend. Manufacturing COGS driven by antigen fermentation, fill‑finish, QC and cold chain; scaling lowers unit fixed costs. SG&A, regulatory, PV and partnership milestones are steady recurring cost centers.
| Cost area | Typical 2024 range (€m) |
|---|---|
| Discovery/preclinical | 1–20 |
| Phase I/II/III | 5–20 / 20–60 / 50–300 |
| Manufacturing/COGS | Variable per dose; fixed scale benefits |
Revenue Streams
Product sales
Product sales in 2024 remained the core revenue stream for Valneva, led by marketed vaccines such as Ixiaro (Japanese encephalitis) and the chikungunya candidate, sold through a mix of public tenders and private channels.
Geographic expansion in 2024 drove volume growth across Asia-Pacific and travel markets, while pricing strategies balanced perceived clinical value with procurement dynamics and tender competition.
Milestones
Milestone payments from Valneva's partner agreements in 2024 are structured around trial progress and regulatory approvals, delivering non-dilutive cash infusions tied to predefined development and regulatory events. These payments accelerate programme funding and shift near-term capital needs to partners. Milestone receipts materially lower funding risk for pipeline programs by de-risking clinical milestones and extending runway for core assets.
Royalties
Royalties paid as a percentage of partner net sales fund Valneva after licensing, for example in Lyme vaccine commercialization deals. In 2024 industry-average vaccine royalty rates ranged 6–8%, producing long-duration cash flows that often persist 10+ years post-launch. Royalties scale with market penetration and align incentives across parties by linking Valneva’s income directly to partner sales growth.
Advance purchases
Advance purchases: Valneva secures prepayments and multi-year supply agreements with governments and agencies to lock capacity, stabilize production planning, and may include take-or-pay provisions that shift demand risk to buyers. These arrangements improve short-term cash visibility and support manufacturing continuity for vaccines and specialized biologics.
- Prepayments and supply agreements
- Capacity secured, production stabilized
- Take-or-pay clauses transfer demand risk
- Improves cash visibility and working capital
Grants and funding
In 2024 Valneva continued to secure non-dilutive support from global health organizations, with grants and advance funding earmarked for specific pathogens and development stages, offsetting R&D and manufacturing readiness costs and preserving equity; this enhances strategic optionality for pipeline prioritization and rapid scale-up.
- Non-dilutive support: grants/advances
- Earmarked: pathogen- or stage-specific
- Offsets: R&D and manufacturing readiness costs
- Benefit: preserves equity, increases strategic optionality
Vaccine sales, 6-8% royalties, 10+yr deals secure cash
Product sales remained Valneva’s core 2024 revenue driver via Ixiaro and travel-market vaccines sold through public tenders and private channels.
Royalties from partner deals averaged 6–8% in 2024, creating long-duration cash flows often persisting 10+ years post-launch.
Advance purchases and take-or-pay supply agreements plus milestone payments and grants provided cash visibility and non-dilutive funding in 2024.
| Stream | 2024 datapoint |
|---|---|
| Royalties | 6–8% rate; 10+ yr duration |